TY - JOUR
T1 - Clinical effectiveness of branded versus generic piperacillin-tazobactam for treating severe community-acquired pneumonia
AU - Wang, Cheng Yi
AU - Chen, Chia Hung
AU - Tu, Chih Yen
AU - Chen, Wei Chih
AU - Kuo, Li Kuo
AU - Wang, Yao Tung
AU - Fu, Pin Kuei
AU - Ku, Shih Chi
AU - Fang, Wen Feng
AU - Chen, Chin Ming
AU - Lai, Chih Cheng
N1 - Publisher Copyright:
© 2022 The Authors
PY - 2022/9
Y1 - 2022/9
N2 - Purpose: To compare the clinical effectiveness of branded versus generic piperacillin-tazobactam for treating severe community-acquired pneumonia (CAP). Patients and methods: We identified patients with severe CAP who received piperacillin-tazobactam based on a nine-center registry database. Furthermore, we classified the patients in three hospitals, which used only branded piperacillin-tazobactam as the study group, and the patients in six other hospitals, which used both branded and generic products as the control group. Results: A total of 472 patients (n = 263 in the study group and n = 209 in the control group) with severe CAP were included. The study group using branded piperacillin-tazobactam had higher odds of clinical cure (adjusted odds ratio [OR] = 3.77, 95 % confidence interval [CI], 1.93–7.37) and lower odds of treatment failure (adjusted OR = 0.28, 95 % CI, 0.13–0.58) than the control group receiving either branded or generic piperacillin-tazobactam. In addition, the study group was associated with higher odds of clinical effectiveness (adjusted OR = 2.95, 95 % CI, 1.46–6.11), less odds of clinical ineffectiveness (adjusted OR = 0.39, 95 % CI, 0.18–0.81), and lower risk of in-hospital mortality (adjusted OR = 0.39, 95 % CI, 0.21–0.73). Conclusion: Based on the findings of the present study using indirect comparison, the clinical effectiveness of generic piperacillin-tazobactam for treating patients with severe CAP might not be as good as that of brand-name products.
AB - Purpose: To compare the clinical effectiveness of branded versus generic piperacillin-tazobactam for treating severe community-acquired pneumonia (CAP). Patients and methods: We identified patients with severe CAP who received piperacillin-tazobactam based on a nine-center registry database. Furthermore, we classified the patients in three hospitals, which used only branded piperacillin-tazobactam as the study group, and the patients in six other hospitals, which used both branded and generic products as the control group. Results: A total of 472 patients (n = 263 in the study group and n = 209 in the control group) with severe CAP were included. The study group using branded piperacillin-tazobactam had higher odds of clinical cure (adjusted odds ratio [OR] = 3.77, 95 % confidence interval [CI], 1.93–7.37) and lower odds of treatment failure (adjusted OR = 0.28, 95 % CI, 0.13–0.58) than the control group receiving either branded or generic piperacillin-tazobactam. In addition, the study group was associated with higher odds of clinical effectiveness (adjusted OR = 2.95, 95 % CI, 1.46–6.11), less odds of clinical ineffectiveness (adjusted OR = 0.39, 95 % CI, 0.18–0.81), and lower risk of in-hospital mortality (adjusted OR = 0.39, 95 % CI, 0.21–0.73). Conclusion: Based on the findings of the present study using indirect comparison, the clinical effectiveness of generic piperacillin-tazobactam for treating patients with severe CAP might not be as good as that of brand-name products.
KW - Brand-name
KW - Community-acquired pneumonia
KW - Effectiveness
KW - Generic name
KW - Piperacillin-tazobactam
UR - http://www.scopus.com/inward/record.url?scp=85135342056&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85135342056&partnerID=8YFLogxK
U2 - 10.1016/j.jiph.2022.07.008
DO - 10.1016/j.jiph.2022.07.008
M3 - Article
C2 - 35930932
AN - SCOPUS:85135342056
SN - 1876-0341
VL - 15
SP - 961
EP - 965
JO - Journal of Infection and Public Health
JF - Journal of Infection and Public Health
IS - 9
ER -